spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  hepatic veno-occlusive disease 

 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Sep 2017
FDA approves Mylotarg for treatment of acute myeloid leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Nov 2013
Defibrotide Granted Orphan Drug Status in Australia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Oct 2013
Gentium Receives Marketing Authorization From the European Commission for Defitelio(R) (Defibrotide)
Biopharmaceuticals Regulatory Product Launch
 HSMN NewsFeed - 26 Jul 2013
Gentium Receives Positive Opinion From EMA's CHMP for Defitelio
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Feb 2013
Gentium Provides Update on the Review of Defibrotide Marketing Authorization
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 May 2012
Gentium Appoints PharmaSwiss, S.A. as Exclusive Distributor of Defibrotide in Central and Eastern European Countries
Biopharmaceuticals Distribution
 HSMN NewsFeed - 27 Feb 2012
The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 Jan 2012
Gentium Appoints Swedish Orphan Biovitrum AB as Exclusive Distributor of Defibrotide in Nordic and Baltic Territories
Biopharmaceuticals Distribution
 HSMN NewsFeed - 29 Dec 2011
Gentium Provides Update on MAA Process for Defibrotide in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Jun 2010
Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Dec 2007
Otsuka Pharmaceutical Acquires Rights to IV Busulfex From PDL BioPharma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jul 2006
Gentium Announces Publication of Two Independent Pediatric Studies of Defibrotide
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
hepatic veno-occlusive disease
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.